DEXCOM INC
DexCom (DXCM) shares are up 34.8% YTD in 2026 after a 14.7% drop in 2025, outperforming the industry and the S&P 500. In Q2, revenue rose 13% YoY and organic growth was 12%. U.S. revenue grew 11% and international 19%. Drivers cited include CGM expansion in non-insulin Type 2 diabetes and G7 15 Day adoption, which improved gross margin by about 400 bps.
DexCom (DXCM) shares rose 52.5% over three months, outpacing the Zacks medical sector and the S&P 500, according to Zacks. In Q2 2026, revenue grew 13.1% to $1.31B and adjusted EPS was 70 cents. Adjusted gross margin rose to 64.1% and operating margin to 25.1%. The stock trades at 30.7x forward earnings versus peers, with competition and litigation risks noted.
DexCom (DXCM) raised its 2026 outlook after a stronger Q2. Q2 revenue was $1.31B (+13.1% YoY) with adjusted EPS of $0.70 and adjusted operating margin of 25.1%. For 2026, management now expects revenue of $5.18-$5.25B, adjusted gross margin ~64%, operating margin 23.5%-24%, and EBITDA margin 31.5%-32%, citing G7 15-day rollout. FX and transition costs remain risks.
Over the past 7 days, alphai's AI scored 4 news stories mentioning DXCM (DEXCOM INC). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Recent DXCM coverage spans earnings, market movers and financial news.
In the last 30 days, DXCM insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($2.6M). The most active reporter was FOLETTA MARK G with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The article frames DXCM’s 2026 uptrend as driven by expanding CGM reimbursement (including non-insulin Type 2) and a product-cycle tailwind from G7 15 Day.
The article frames DXCM’s upside as dependent on sustaining earnings growth, margin gains, and G7 15 Day adoption despite premium valuation and litigation risk.
Guidance upside and margin expansion improve the profitability trajectory, but FX, G6-to-G7 transition costs, and competition add execution risk.
Higher Q2 results plus an upgraded 2026 revenue range strengthens the near-term demand narrative for DexCom’s CGM portfolio, but CMS pricing and execution risks remain.
Forecast range and the 52-week-high reaction create a tradable momentum setup for DXCM.
alphai scores every news story that mentions DXCM with an AI model for sentiment and relevance, and aggregates insider trades from DEXCOM INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
DexCom (DXCM) shares are up 34.8% YTD in 2026 after a 14.7% drop in 2025, outperforming the industry and the S&P 500. In Q2, revenue rose 13% YoY and organic growth was 12%. U.S. revenue grew 11% and international 19%. Drivers cited include CGM expansion in non-insulin Type 2 diabetes and G7 15 Day adoption, which improved gross margin by about 400 bps.
6 min readDexCom (DXCM) shares rose 52.5% over three months, outpacing the Zacks medical sector and the S&P 500, according to Zacks. In Q2 2026, revenue grew 13.1% to $1.31B and adjusted EPS was 70 cents. Adjusted gross margin rose to 64.1% and operating margin to 25.1%. The stock trades at 30.7x forward earnings versus peers, with competition and litigation risks noted.
6 min readDexCom (DXCM) raised its 2026 outlook after a stronger Q2. Q2 revenue was $1.31B (+13.1% YoY) with adjusted EPS of $0.70 and adjusted operating margin of 25.1%. For 2026, management now expects revenue of $5.18-$5.25B, adjusted gross margin ~64%, operating margin 23.5%-24%, and EBITDA margin 31.5%-32%, citing G7 15-day rollout. FX and transition costs remain risks.
5 min readDexCom reported Q2 2026 sales of $1,308.4 million and net income of $249.1 million, both higher than the prior year, and raised full-year 2026 revenue guidance to $5.18 billion to $5.25 billion, according to the company. The article says the update may affect the investment case amid risks like CMS pricing pressure and execution.
6 min readAmazon shares rose after Q2 results, with revenue up 20% Y/Y to $200.6B and AWS revenue up 36.7% to $42.2B. Dexcom hit a 52-week high after Q2 results and a 2026 revenue outlook of $5.18B to $5.25B. Corteva fell after Q2 revenue of $6.38B, but raised guidance, with operating EBITDA above $4.3B. Coinbase dropped after Q2 GAAP EPS of -$1.36 and weaker Q3 subscription and services revenue.
6 min readDexCom (DXCM) reported Q2 2026 results with higher sales and earnings and raised full-year revenue guidance to about $5.18b to $5.25b. The stock has risen sharply recently. Simply Wall St discusses valuation versus a $91.64 fair value estimate and notes reimbursement expansion and CGM coverage, alongside risks from Medicare pricing pressure and competition.
5 min readU.S. S&P 500 and Nasdaq 100 E-mini futures rose as WTI crude fell more than 6% after President Trump called off a strike on Iran and said talks would start Monday. Treasuries rose, with the 10-year yield down to 4.69%. The article cites recent stock moves in AMZN, DXCM, MPWR, and AAPL, and outlines upcoming earnings, Fed speakers, and U.S. jobs data.
7 min readDexCom (DXCM) reported Q2 2026 revenue of $1.31B, up 13% reported and 12% organic year over year. Non-GAAP gross margin was 64.1%, non-GAAP operating income $328.3M, and non-GAAP EPS $0.70. Free cash flow was $600M in H1. FY2026 revenue guidance raised to $5.18B-$5.25B. The company completed the Nutrisense acquisition and discussed CONNECT trial and G7 15-day progress.
10 min readAfter Amazon’s Q2 results, AMZN shares rose 17% last week. Revenue grew 20% Y/Y to $200.6B, with AWS up 36.7% Y/Y to $42.2B. Dexcom (DXCM) hit a 52-week high on Q2 results and a 2026 revenue forecast of $5.18B to $5.25B. Corteva (CTVA) fell ~12% despite guidance; Coinbase (COIN) dropped after Q2 GAAP EPS of -$1.36 and Q3 subscription/services revenue up to $580B.
6 min readDexCom (NASDAQ: DXCM) shares rose about 11% after a Q2 beat and bullish sentiment around its CGM growth. The company reported Q2 revenue of about $1.31B, up 13% YoY, and adjusted EPS of $0.70 vs $0.61 consensus. The article cites raised 2026 guidance and technical breakout levels near $80 support.
6 min read
